Latent Toxoplasmosis in Females With Borderline Personality Disorder
Key facts
- Who runs it
- Marie Ociskova
- Where
- Czechia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 1 Jan 2021
- Ended
- 1 Apr 2024
- Type of study
- Observational
- Treatments tested
- Combined schema-therapy and cognitive behavioral therapy
- Psychopharmaceuticals
- Record updated
- 2 April 2024
- Why it stopped
- Funding issues
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Adult
- Female
- Borderline personality disorder diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders-5 criteria
- Signed informed consent
Who cannot take part
- Current substance abuse disorder
- Psychotic disorder, bipolar disorder, organic mental disorder current or past
- Severe somatic illness (e.g., endocrinopathy, oncologic, hematologic, cardiologic, or neurologic illness)
- Severe suicidal risk
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Borderline personality disorder is a common mental disorder with core features of affective dysregulation, impulsivity, and identity disturbance. Although this disorder is mostly understood as a result of a combination of biological factors (genes, temperament) and early aversive experiences (often of traumatic nature), recent data suggest that other factors may be important in its development and course. Preliminary findings show that patients with borderline personality disorder have higher prevalence of Toxoplasma seropositivity. This infection may manifest in symptoms such as affective dysregulation, aggression, suicidality, or anxiousness. As such, it may play a role in the psychopathology of the borderline personality disorder. The aim of this study is to explore the prevalence of Toxoplasma seropositivity in a sample of females with borderline personality disorder, its clinical correlates, and a potential impact on outcomes of an intensive six-week inpatient schema-therapeutic treatment. Results may enrich our understanding of this disorder and lead to improvements of the therapeutic approaches.
The group in the trial
- Females with borderline personality disorder
Treatment: Combined schema-therapy and cognitive behavioral therapy and Psychopharmaceuticals
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Latent Toxoplasmosis in Females With Borderline Personality Disorder - Occurrence, Clinical Features, and Impact on Effectiveness of Combined Pharmacotherapeutic and Psychotherapeutic Treatment
- Record updated
- 2 April 2024